DCP与AFP-L3在预测肝移植高危移植物特征中与AFP互补:前瞻性研究结果
该前瞻性研究探讨在肝细胞癌(HCC)肝移植(LT)中,DCP与AFP-L3是否可与AFP互补预测高危移植物特征。背景指出AFP升高可预测等待名单脱落、高危病理特征及移植后不良结局,但许多AFP正常患者仍出现脱落或复发,故需其他生物标志物。AFP-L3与DCP已用于HCC监测或诊断,但其在LT中的效用尚未确立。
要点
- AFP升高可预测HCC肝移植等待名单脱落、高危病理特征及移植后不良结局。
- 许多AFP正常的HCC患者仍发生等待名单脱落或移植后复发。
- DCP与AFP-L3在肝移植中预测高危移植物特征的效用尚未确立。
核心结论
- DCP与AFP-L3在预测肝移植高危移植物特征方面与AFP互补。
研究设计与样本
- 前瞻性研究,评估DCP与AFP-L3在HCC肝移植中与AFP互补预测高危移植物特征。
主要发现
- AFP升高可预测等待名单脱落、高危病理特征及移植后不良结局。
- 许多AFP正常的HCC患者仍出现等待名单脱落或移植后复发。
- DCP与AFP-L3在肝移植中的效用尚未确立。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Among patients with hepatocellular carcinoma (HCC), elevated α-fetoprotein (AFP) has been shown to predict waitlist dropout, high-risk histopathologic features, and inferior post-liver transplant (LT) outcome.1,2 Nevertheless, many patients with HCC have a normal AFP and yet still experience waitlist dropout or post-LT recurrence.2 Because of the degree of imprecision associated with AFP, there is a quest for other biomarkers that may be complementary to or better than AFP in predicting prognosis in LT. Lectin-reactive AFP (AFP-L3) and des-gamma-carboxyprothrombin (DCP) are biomarkers that have been used in conjunction with AFP as HCC surveillance or diagnostic tools.3,4 However, the utility of these biomarkers in LT for HCC is not established.
引用
- Kotwani P, Chan W, Yao F, et al. DCP and AFP-L3 Are Complementary to AFP in Predicting High-Risk Explant Features: Results of a Prospective Study. Clin Gastroenterol Hepatol. 2021. PMID: 33524592. doi:10.1016/j.cgh.2021.01.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。